The Food and Drug Administration approved on Friday that Wegovy, a version of the diabetes drug that can now be marketed and sold as a diet pill in the United States.
Why is this important: This drug has helped some people lose an average of 15% weight over several weeks. When used in conjunction with increased exercise and lower calorie diet plans
How it works: This medication is a higher dose of Novo Nordisk’s diabetes drug semalutide. It is intended for people with a body mass index (BMI) of 27 kg/m² or more and at least one weight-related condition, or those with a body mass index of 30 kg/m² or higher. go
- shoot every week It mimics intestinal hormones that target areas of the brain that control appetite and food intake. and is intended for long-term weight management.
- People who took Wegovy and exercised and dieted in the company-funded study lost significantly more weight over a 14-week period than those taking a placebo during exercise and diet.
What are they saying: “Today’s approval gives obese or overweight adults a useful new treatment option to integrate into a weight management program,” said John Sharretts, deputy director of the diabetes division. Lipid Disorders and Obesity in the FDA’s Center for Drug Evaluation and Research .
- Yes, but: Dr. Archana Sadhu, head of the diabetes program at Houston Methodist Hospital, told the AP that the drug’s effectiveness will depend largely on its price.
- Novo Nordisk hasn’t revealed a price for Wegovy yet.
The big picture: About 70% of American adults are obese or overweight. which can lead to heart disease Stroke, diabetes and an increased risk of developing certain cancers. According to the Food and Drug Administration (FDA),
- A 5% weight loss from diet and exercise was associated with a reduced risk of cardiovascular disease in obese or overweight adults.
- Wegovy was the first FDA-approved drug for chronic weight management since 2014.